Skip to main content
NCBI home page
Gut logoLink to Gut
. 1996 Feb;38(2):223–228. doi: 10.1136/gut.38.2.223

Increased degradation of type I collagen in patients with inflammatory bowel disease.

J Silvennoinen 1, L Risteli 1, T Karttunen 1, J Risteli 1
PMCID: PMC1383027  PMID: 8801201

Abstract

To assess the mechanisms of osteopenia in inflammatory bowel disease (IBD), the serum markers of bone formation (osteocalcin and carboxyterminal propeptide of type I procollagen (PICP)) and bone degradation (carboxyterminal telopeptide of type I collagen (ICTP)), the bone mineral density (BMD) of the lumbar spine and the proximal femur and calcium intake of 150 unselected IBD patients and 73 healthy controls were investigated. The patients had higher ICTP values (3.69 (SD 1.40) microgram/l) than the healthy controls (3.25 (1.00) microgram/l, p = 0.035), but no differences in serum PICP and osteocalcin between these groups were detected. In the patients, the ICTP, PICP, and osteocalcin values did not have any significant correlation with BMD, but the patients with ICTP values above 3.6 microgram/l had significantly lower Z scores than those with lower ICTP. In the controls, however, a positive correlation between serum ICTP and BMD was found. The ulcerative colitis patients with total colitis had higher values of ICTP (3.96 (1.58) microgram/l) than those with a left sided disease (3.04 (0.86) micrograms/l, p = 0.009). The patients with a history of clinically active disease (n = 20) had higher ICTP (4.58 (1.55) microgram/l) and osteocalcin (12.56 (5.64) microgram/l) values than the patients (n = 130) with quiescent disease (ICTP 3.56 (1.33), p = 0.002, and osteocalcin 9.76 (3.62), p = 0.017). Increased serum osteocalcin, PICP, and ICTP concentrations and reduced BMD Z scores were found in a subgroup of Crohn's disease patients with a history of an active disease (n = 11). Raised serum ICTP and normal values of osteocalcin and PICP in IBD patients show increased breakdown of type I collagen without a compensatory increase in its synthesis suggesting an increased rate of bone degradation as a probable mechanism for osteopenia in IBD. Raised ICTP values are related to reduced bone mineral densities.

Full text

PDF
223

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Charles P., Mosekilde L., Risteli L., Risteli J., Eriksen E. F. Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner. 1994 Feb;24(2):81–94. doi: 10.1016/s0169-6009(08)80147-x. [DOI] [PubMed] [Google Scholar]
  2. Chong S. K., Blackshaw A. J., Boyle S., Williams C. B., Walker-Smith J. A. Histological diagnosis of chronic inflammatory bowel disease in childhood. Gut. 1985 Jan;26(1):55–59. doi: 10.1136/gut.26.1.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Compston J. E., Judd D., Crawley E. O., Evans W. D., Evans C., Church H. A., Reid E. M., Rhodes J. Osteoporosis in patients with inflammatory bowel disease. Gut. 1987 Apr;28(4):410–415. doi: 10.1136/gut.28.4.410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Elomaa I., Virkkunen P., Risteli L., Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer. 1992 Aug;66(2):337–341. doi: 10.1038/bjc.1992.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Eriksen E. F., Charles P., Melsen F., Mosekilde L., Risteli L., Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res. 1993 Feb;8(2):127–132. doi: 10.1002/jbmr.5650080202. [DOI] [PubMed] [Google Scholar]
  6. Hakala M., Risteli L., Manelius J., Nieminen P., Risteli J. Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis. Ann Rheum Dis. 1993 Dec;52(12):866–869. doi: 10.1136/ard.52.12.866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Haukipuro K., Melkko J., Risteli L., Kairaluoma M., Risteli J. Synthesis of type I collagen in healing wounds in humans. Ann Surg. 1991 Jan;213(1):75–80. doi: 10.1097/00000658-199101000-00013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jensen L. T., Olesen H. P., Risteli J., Lorenzen I. External thoracic duct-venous shunt in conscious pigs for long term studies of connective tissue metabolites in lymph. Lab Anim Sci. 1990 Nov;40(6):620–624. [PubMed] [Google Scholar]
  9. Kotaniemi A., Isomäki H., Hakala M., Risteli L., Risteli J. Increased type I collagen degradation in early rheumatoid arthritis. J Rheumatol. 1994 Sep;21(9):1593–1596. [PubMed] [Google Scholar]
  10. Kröger H., Heikkinen J., Laitinen K., Kotaniemi A. Dual-energy X-ray absorptiometry in normal women: a cross-sectional study of 717 Finnish volunteers. Osteoporos Int. 1992 May;2(3):135–140. doi: 10.1007/BF01623820. [DOI] [PubMed] [Google Scholar]
  11. Kröger H., Laitinen K. Bone mineral density measured by dual-energy X-ray absorptiometry in normal men. Eur J Clin Invest. 1992 Jul;22(7):454–460. doi: 10.1111/j.1365-2362.1992.tb01490.x. [DOI] [PubMed] [Google Scholar]
  12. Kylmälä T., Tammela T., Risteli L., Risteli J., Taube T., Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer. 1993;29A(6):821–825. doi: 10.1016/s0959-8049(05)80417-4. [DOI] [PubMed] [Google Scholar]
  13. Melkko J., Niemi S., Risteli L., Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem. 1990 Jul;36(7):1328–1332. [PubMed] [Google Scholar]
  14. Oikarinen A., Autio P., Kiistala U., Risteli L., Risteli J. A new method to measure type I and III collagen synthesis in human skin in vivo: demonstration of decreased collagen synthesis after topical glucocorticoid treatment. J Invest Dermatol. 1992 Feb;98(2):220–225. doi: 10.1111/1523-1747.ep12555884. [DOI] [PubMed] [Google Scholar]
  15. Oikarinen A., Autio P., Vuori J., Vänänen K., Risteli L., Kiistala U., Risteli J. Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen. Br J Dermatol. 1992 Feb;126(2):172–178. doi: 10.1111/j.1365-2133.1992.tb07816.x. [DOI] [PubMed] [Google Scholar]
  16. Pera A., Bellando P., Caldera D., Ponti V., Astegiano M., Barletti C., David E., Arrigoni A., Rocca G., Verme G. Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and proposal of an endoscopic score. Gastroenterology. 1987 Jan;92(1):181–185. [PubMed] [Google Scholar]
  17. Pigot F., Roux C., Chaussade S., Hardelin D., Pelleter O., Du Puy Montbrun T., Listrat V., Dougados M., Couturier D., Amor B. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci. 1992 Sep;37(9):1396–1403. doi: 10.1007/BF01296010. [DOI] [PubMed] [Google Scholar]
  18. Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 1993 Apr;39(4):635–640. [PubMed] [Google Scholar]
  19. Rutegård I., Ahsgren L., Stenling R., Nilsson T. A simple index for assessment of disease activity in patients with ulcerative colitis. Hepatogastroenterology. 1990 Dec;37 (Suppl 2):110–112. [PubMed] [Google Scholar]
  20. Silvennoinen J. A., Karttunen T. J., Niemelä S. E., Manelius J. J., Lehtola J. K. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut. 1995 Jul;37(1):71–76. doi: 10.1136/gut.37.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Välimäki M. J., Kärkkäinen M., Lamberg-Allardt C., Laitinen K., Alhava E., Heikkinen J., Impivaara O., Mäkelä P., Palmgren J., Seppänen R. Exercise, smoking, and calcium intake during adolescence and early adulthood as determinants of peak bone mass. Cardiovascular Risk in Young Finns Study Group. BMJ. 1994 Jul 23;309(6949):230–235. doi: 10.1136/bmj.309.6949.230. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES